University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Mi-Ok Kim, PhD

Mi-Ok Kim, PhD

Director, Biostatistics Core, UCSF Helen Diller Family Comprehensive Cancer Center
Professor in Residence, Dept. of Epidemiology & Biostatistics, UCSF

Cancer Center Program Memberships

Cancer Control

Research Summary

Dr. Mi-Ok Kim has joined the HDFCCC as Director of the Biostatistics Core. The Core is responsible for providing support for protocol development, review and analysis for clinical studies, and statistical expertise for research collaborations with Cancer Center investigators in all disciplines across the spectrum of basic, clinical and population sciences. Dr. Kim will lead the Core and work directly with Cancer Center leadership on developing and implementing a strategic and integrated shared resource plan.

Dr. Kim joins us from Cincinnati Children’s Hospital Medical Center in Cincinnati, OH, where she directed the Biostatistics Unit for the Cancer and Blood Diseases Institute. Notable collaborations included Children's Tumor Foundation’s Neurofibromatosis (NF) Therapeutic Consortium that builds up a preclinical pipeline for screening candidate drug therapies in animal model systems. Dr. Kim also developed a research program in novel clinical trial designs that incorporate biomarker information and aim to optimize patient benefits. With the expertise in the trial design she served on the faculty for the American Association for Cancer Research (AACR) sponsored 2015 Methods in Cancer Biostatistics Workshop.

Dr. Kim will also join the Department of Epidemiology and Biostatistics as Professor of Biostatistics, continuing academic contributions to the field of biostatistics and providing biostatistical support broadly on campus. Trained as a mathematical statistician, Dr. Kim is an independent statistical method researcher with research interest in non- and semi-parametric statistics, and longitudinal and survival data analysis. She has been supported by NIH and National Science Foundation (NSF) awards, and published in prestigious journals such as the Annals of Statistics and the Journal of the American Statistical Association. Her recent research focuses on causal inference using structured data for comparative effectiveness research (CER) and patient-centered outcome research (PCOR). Registries, network databases and Electronic Health Record (EHR) often impose a hierarchical structure where subjects or patients are clustered, for example, by geographical area of residence, health care provider or health plan. The data structure is often associated with unmeasured characteristics of individuals or health care providers. Supported by the Patient-Centered Outcome Research Institute (PCORI), Dr. Kim and her research team study optimal handling of the complex data structure both in the treatment selection decision process and the outcome analysis in order to minimize bias and maximize efficiency of the causal inference. Application studies of the project include pediatric Crohn’s disease (CD) and kidney transplant study.


MS: Statistics, University of Illinois, Urbana-Champaign, IL, 2000
PhD: Statistics, University of Illinois, Urbana-Champaign, IL, 2003

Professional Experience

  • 2003 - 2006
    University of Kentucky, Assistant Professor, Department of Statistics and Biostatistics
  • 2006 - 2010
    University of Cincinnati College of Medicine Assistant Professor of Pediatrics Department of Pediatrics/ Division of Biostatistics and Epidemiology
  • 2008 - 2010
    University of Cincinnati, Assistant Professor (Affiliated), Department of Mathematical Sciences
  • 2010 - 2016
    University of Cincinnati College of Medicine Associate Professor, Department of Pediatrics/ Division of Biostatistics and Epidemiology
  • 2010 - 2016
    University of Cincinnati, Associate Professor (Affiliated), Department of Mathematical Sciences
  • 2016 - present
    Director, Biostatistics Core, UCSF Helen Diller Family Comprehensive Cancer Center

Honors & Awards

  • 1997
    Fellowship,University of Illinois at Urbana-Champaign
  • 2001
    First Prize,Capital One Financial Data Challenge Competition2002
    Norton Prize, Robert Bohrer Workshop for Student Papers in Statistics, University of Illinois at Urbana-Champaign
  • 2004
    Junior Faculty Travel Award,International Conference on Robust Statistics (ICORS)
  • 2008
    Travel Award, American Association for Cancer Research (AACR) Cancer Biostatistics Workshop

Selected Publications

  • Kim MO*, “Quantile Regression with Varying Coefficients”. Annals of Statistics, 2007. 35(1): p. 92-108, MathSciNet Mathematical Review (MR) ID: MR2332270
  • Kim MO and Yang Y, “Semiparametric Approach to a Random Effects Quantile Regression Model”, Journal of the American Statistical Association, 2011, Dec 1: 106(496): 1405-1417, PMID:22347760, NIHMSID #299346
  • Choi D, Hoffman KA, Kim MO, McCarty D, "A High Resolution Evaluation of Process Improvement: Use of Quantile Regression for Wait Time", Health Services Research, 2013 Feb;48(1):333-47, PMID: 22716460
  • Hoskins EE, Morreale RJ, Werner SP, Higginbotham JM, Laimins LA, Lambert PF, Brown DR, Gillison ML, Nuovo GJ, Witte DP, Kim MO, Davies SM, Mehta PA, Kovacic MB, Wikenheiser-Brokamp KA, Wells SI., "The Fanconi Anemia Pathway Limits Human Papillomavirus Replication", Journal of Virology, 2012 Aug;86(15):8131-8. doi: 10.1128/JVI.00408-12, PMID: 2262378
  • Marsh RA, Rao K, Satwani P, Lehmberg K, Muller I, Li D, Kim MO, Fischer A, Latour S, Sedlacek P, Barlogis V, Hamamoto K, Kanegane H, Milanovich S, Margolis DA, Dimmock D, Casper JT, Douglas DN, Amrolia PJ, Veys P, Kumar A, Jordan MB, Bleesing J, and Filipovich L, "Allogeneic Hematopoietic Cell Transplantation for XIAP Deficiency: An International Survey Reveals Poor Outcomes", Blood, 2013 Feb 7;121(6):877-83, PMID: 23131490
  • Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, Kim MO, West BL, Bollag G, Ratner N, "Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition", Acta Neuropathologica, 2013 Jan;125(1):159-68, PMID: 23099891
  • Gathungu G, Kim MO, Ferguson JP, Sharma Y, Zhang W, Ng SM, Bonkowski E, Ning K, Simms LA, Croft AR, Stempak JM, Walker N, Huang N, Xiao Y, Silverberg MS, Trapnell B, Cho JH, Radford-Smith GL, Denson LA., "Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies: A Marker of Aggressive Crohn's Disease", Inflammatory Bowel Diseases, 2013 Jul;19(8):1671-1680, PMID: 23749272
  • Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Eaves D, Widemann B, Kim MO, Dombi E, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N, "MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors", Journal of Clinical Investigation, 2013 Jan 2;123(1):340-7, PMID: 23221341
  • Dykes DM, Towbin AJ, Bonkowski E, Chalk C, Bezold R, Lake K, Kim MO, Heubi JE, Trapnell BC, Podberesky DJ, Denson LA., "Increased Prevalence of Luminal Narrowing and Stricturing Identified by Enterography in Pediatric Crohn's Disease Patients With Elevated Granulocyte-Macrophage Colony Stimulating Factor Autoantibodies", Inflammatory Bowel Diseases, 2013 Sep;19(10):2146-54, PMID: 23893081
  • Kim MO*, Liu C, Hu F, Lee JJ, "Outcome-Adaptive Randomization for a Delayed Outcome with a Short-Term Predictor: Imputation Based Designs", Statistics in Medicine, 2014 Oct 15;33(23):4029-42, PMID: 24889540
  • Rose SR, Kim MO, Korbee L, Wilson KA, Douglas Ris M, Eyal O, Sherafat-Kazemzadeh R, Bollepalli S, Harris R, Jeng MR, Williams DA, Smith FO., "Oxandrolone for the Treatment of Bone Marrow Failure in Fanconi Anaemia", Pediatric Blood & Cancer, 2014 Jan;61(1):11-9, PMID: 24019220
  • Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, Mays M, Lopez CM, Kim MO, Franz DN, "Everolimus Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex", Annals of Neurology, 2013 Nov;74(5):679-87, PMID: 23798472
  • Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M, Kumar A, Jodele S, Myers KC, Chandra S, Leemhuis T, Mehta P, Bleesing JJ, Davies SM, Jordan MB, Filipovich AH, "An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis", Biol Blood Marrow Transplant, 2013 Nov;19(11):1625-31, PMID: 24035782
  • Walters TD, Kim MO*, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, Baldassano R, Crandall W, Rosh J, Pfefferkorn M, Otley A, Heyman MB, LeLeiko N, Baker S, Guthery SL, Evans J, Ziring D, Kellermayer R, Stephens M, Mack D, Oliva-Hemker M, Patel AS, Kirschner B, Moulton D, Cohen S, Kim S, Liu C, Essers J, Kugathasan S, Hyams JS; PRO-KIIDS Research Group, "Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease", Gastroenterology, 2014 Feb;146(2):383-91, PMID: 24162032 (*co-primary authors)
  • Minar P, Haberman Y, Jurickova I, Wen T, Rothenberg ME, Kim MO, Saeed SA, Baldassano RN, Stephens M, Markowitz J, Rosh J, Crandall WV, Heyman MB, Mack DR, Griffiths AM, Baker SS, Hyams JS, Kugathasan S, Denson LA, "Utility of Neutrophil Fcγ Receptor I (CD64) Index as a Biomarker for Mucosal Inflammation in Pediatric Crohn's Disease", Inflammatory Bowel Diseases. 2014 Jun;20(6):1037-48, PMID: 2478821
  • Haberman Y, Tickle TL, Dexheimer PJ, Kim MO, Tang D, Karns R, Baldassano RN, Noe JD, Rosh J, Markowitz J, Heyman MB, Griffiths AM, Crandall WV, Mack DR, Baker SS, Huttenhower C, Keljo DJ, Hyams JS, Kugathasan S, Walters TD, Aronow B, Xavier RJ, Gevers D, Denson LA, "Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature", Journal of Clinical Investigation. 2014 Aug 1;124(8):3617-33, PMID: 25003194
  • Nehus E, Liu C, Hooper DK, Macaluso M, and Kim MO, "Clinical Practice of Steroid-Avoidance Protocols in Pediatric Kidney Transplant Recipients", American Journal of Transplantation, 2015 Aug;15(8):2203-10
  • Jousma E, Rizvi TA, Wu J, Janhofer D, Dombi E, Dunn RS, Kim MO, Masters AR, Jones DR, Cripe TP, Ratner N, "Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1", Pediatr Blood Cancer. 2015 Apr 22. doi: 10.1002/pbc.25546. PMID: 25907661
  • Phillip Minar, Shehzad Saeed, Mahrukh Afreen, Mi-Ok Kim, Lee A. Denson, "Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn's Disease". Journal Pediatr Gastroenterol Nutr. 2015, Nov. PMID: 26551317
  • Haberman, Y, Tickle TL, Dexheimger PJ, Kim MO, Tang D, Karns R, Baldassano RN, Noe JD, Rosh J, Markowitz J, Heyman MB, Griffiths AM, Crandall WV, Mack DR, Baker SS, Huttenhower C, Keljo DJ, Hyams JS, Kugathasan S, Walter TD, Aronow B, Xavier RJ, Gevers D, Denson LA. "Corrigendum. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature". J Clin Invest. 2015 Mar 2;125(3): 1363. doi: 10.1172/JCI79657. PMID: 25729854
  • Wu J, Keng VW, Patmore DM, Kendall JJ, Patel AV, Jousma E, Jessen WJ, Choi K, Tschida BR, Silverstein KA, Fan D, Schwartz EB, Fuchs JR, Zou Y, Kim MO, Dombi E, Levy DE, Huang G, Cancelas JA, Stemmer-Rachamimov AO, Spinner RJ, Largaespada DA, Ratner N., "Insertional mutagenesis identifies a STAT3/Arid1b/β-catenin pathway driving neurofibroma", Cell Rep. 2016 Mar 1;14(8):1979-90. PMID: 2690493
  • Cho H, Hong HG, Kim MO*, "Efficient Quantile Regression Analysis of Longitudinal Data with Dropouts", Biostatistics, 2016 Mar, PMID:26951723